Zacks Research Weighs in on Stryker's Q4 Earnings (NYSE:SYK)

Stryker Co. (NYSE:SYK - Free Report) - Zacks Research boosted their Q4 2025 earnings estimates for shares of Stryker in a research report issued on Tuesday, February 18th. Zacks Research analyst I. Bandyopadhyay now expects that the medical technology company will post earnings per share of $4.34 for the quarter, up from their previous forecast of $4.23. The consensus estimate for Stryker's current full-year earnings is $13.49 per share. Zacks Research also issued estimates for Stryker's Q4 2026 earnings at $4.65 EPS and FY2027 earnings at $16.40 EPS.

Other analysts also recently issued reports about the company. Wells Fargo & Company increased their target price on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Canaccord Genuity Group lifted their price objective on Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a report on Wednesday, January 29th. Evercore ISI boosted their target price on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Stifel Nicolaus raised their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $420.68.

Stryker Stock Down 1.0 %

Shares of NYSE SYK traded down $3.82 during trading on Thursday, reaching $382.59. The company had a trading volume of 1,268,413 shares, compared to its average volume of 1,388,856. Stryker has a 12-month low of $314.93 and a 12-month high of $406.19. The business's 50-day moving average is $377.92 and its 200 day moving average is $368.21. The stock has a market cap of $145.99 billion, a PE ratio of 49.30, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business earned $3.46 earnings per share.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker's dividend payout ratio is currently 43.30%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Hedge Funds Weigh In On Stryker

Several institutional investors have recently bought and sold shares of SYK. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $25,000. Dunhill Financial LLC increased its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Rakuten Securities Inc. raised its position in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at approximately $30,000. Finally, BankPlus Trust Department purchased a new position in shares of Stryker in the 4th quarter worth approximately $33,000. Institutional investors own 77.09% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.